Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,758 matching trials from the live ClinicalTrials.gov search.
Conditions
Lung Cancer
Interventions
AMG 510, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Los Angeles, California • Jacksonville, Florida • Winter Haven, Florida + 11 more
Conditions
Non-Small Cell Lung Cancer
Interventions
Gemcitabine, Cisplatin, IMC-A12 (cixutumumab), Cetuximab, Carboplatin
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Anniston, Alabama • La Jolla, California • Orange, California + 6 more
Conditions
Lung Cancer
Interventions
Standard Radiation Dose Therapy, cisplatin, etoposide, High Radiation Dose Therapy, carboplatin
Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
930
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 575 more
Conditions
Lung Neoplasm Malignant
Interventions
Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Carboplatin, Pembrolizumab (adjuvant), Paclitaxel, Steroid mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
9
States / cities
Daphne, Alabama • Santa Barbara, California • Lone Tree, Colorado + 5 more
Conditions
Solid Tumor
Interventions
Taxotere, Cisplatin, CPT-11
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Sarcoma
Interventions
cisplatin, doxorubicin hydrochloride, mitomycin C
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
54
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 43 more
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Carboplatin, Gemcitabine, Placebo, Cisplatin
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more
Conditions
Metastatic Melanoma
Interventions
Biochemo + bevacizumab then ipilimumab
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Conditions
Malignant Pleural Mesothelioma
Interventions
Extrapleural pneumonectomy (EPP), Cisplatin, gemcitabine, amifostine, sodium thiosulfate, Pleurectomy/Decortication
Procedure · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Abemaciclib, Nivolumab, Tumor biopsy, Peripheral blood, EORTC QLQ-30
Drug · Procedure · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
Interventions
Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin, Cisplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Docetaxel, Nivolumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
Tucson, Arizona • Fort Wayne, Indiana • Lexington, Kentucky + 3 more
Conditions
Advanced Solid Tumors
Interventions
CS2009, Pemetrexed, Carboplatin, Paclitaxel, Etoposide, Nab-paclitaxel, Oxaliplatin, Capecitabine, Docetaxel, Leucovorin, 5-FU, Cisplatin, Gemcitabine, Irinotecan
Drug
Lead sponsor
CStone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Irving, Texas
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Thoracic Radiotherapy, Durvalumab
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more
Conditions
Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Interventions
S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm), Fluorouracil/cisplatin (control arm)
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Alexandria, Louisiana • Albuquerque, New Mexico • Dallas, Texas + 1 more
Conditions
Gastric Cancer, Peritoneal Carcinomatosis
Interventions
Cisplatin, Mitomycin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, EGFR Exon 20 Mutation, EGFR Exon 20 Insertion Mutation, EGFR Activating Mutation, Antineoplastic Agents, Metastatic Lung Cancer, Brain Metastases, EGFR-mutated NSCLC, EGFR Atypical Mutations, Including G719X and L861Q
Interventions
BLU-451, Carboplatin, Pemetrexed
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more
Conditions
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
Interventions
amifostine trihydrate, cisplatin, radiation therapy
Drug · Radiation
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7
Interventions
Bevacizumab, Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
103
States / cities
Burbank, California • Sacramento, California • Colorado Springs, Colorado + 73 more
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
66
States / cities
Mobile, Alabama • Phoenix, Arizona • Duarte, California + 54 more
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Tirapazamine, Cisplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Head and Neck Cancer
Interventions
cisplatin, vandetanib, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
63
States / cities
Scottsdale, Arizona • Duarte, California • La Jolla, California + 52 more
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Consolidative Surgery
Drug · Procedure
Lead sponsor
Jason R. Brown
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
9
States / cities
Indianapolis, Indiana • St Louis, Missouri • Albuquerque, New Mexico + 3 more
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2001
U.S. locations
2
States / cities
Baltimore, Maryland